Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
22. September 2021 09:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress
22. September 2021 08:30 ET
|
Akari Therapeutics Plc
Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP).Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic...
Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium
10. September 2021 08:30 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference
07. September 2021 07:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Announces Private Placement
07. Juli 2021 09:15 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to...
Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress
29. Juni 2021 16:01 ET
|
Akari Therapeutics Plc
Open Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid (BP) Phase III study of nomacopan in severe...
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid
28. April 2021 08:00 ET
|
Akari Therapeutics Plc
A multicenter Phase III study of nomacopan for the treatment of moderate and severe bullous pemphigoid (BP) has been initiatedNomacopan has potential to replace long term steroid treatment (standard...
Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience
22. April 2021 07:30 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, April 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...
Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress
20. April 2021 18:40 ET
|
Akari Therapeutics Plc
Opening of Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid (BP), a severe dermatological disease with no...
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
12. April 2021 10:16 ET
|
Akari Therapeutics Plc
FDA investigational new drug application (IND) now open Clinical sites expected to open for recruitment mid-2021 NEW YORK and LONDON, April 12, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc...